Dystroglycan: a possible mediator for reducing congenital muscular dystrophy?

Trends Biotechnol. 2007 Jun;25(6):262-8. doi: 10.1016/j.tibtech.2007.04.002. Epub 2007 Apr 9.

Abstract

Alpha-dystroglycan is a highly glycosylated peripheral protein forming a complex with the membrane-spanning beta-dystroglycan and establishing a connection between the extracellular matrix and the cytoskeleton. In skeletal muscle, as part of the larger dystrophin-glycoprotein complex, dystroglycan is believed to be essential for maintaining the structural and functional stability of muscle fibers. Recent work highlights the role of abnormal dystroglycan glycosylation at the basis of glycosyltransferase-deficient congenital muscular dystrophies. Notably, modulation of glycosyltransferase activity can restore alpha-dystroglycan receptor function in these disorders. Moreover, transgenic approaches favoring the interaction between dystroglycan and the extracellular matrix molecules also represent an innovative way to restore skeletal muscle structure. These pioneering approaches might comprise an important first step towards the design of gene-transfer-based strategies for the rescue of congenital muscular dystrophies involving dystroglycan.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Dystroglycans / genetics*
  • Dystroglycans / metabolism*
  • Extracellular Matrix / metabolism*
  • Gene Targeting / methods
  • Genetic Therapy / methods
  • Humans
  • Mice
  • Models, Biological
  • Muscle, Skeletal / physiopathology*
  • Muscular Dystrophies / congenital*
  • Muscular Dystrophies / physiopathology*
  • Muscular Dystrophies / therapy

Substances

  • Dystroglycans